Results 11 to 20 of about 125,484 (349)

Proton-pump inhibitors and risk of renal disease [PDF]

Journal of Nephropharmacology, 2017
Proton pump inhibitors (PPIs) are one group of drugs that inhibit gastric acid secretion by binding irreversibly to the gastric proton pump to the gastric proton pump.
Mahrang Hedaiaty, Mohammad Reza Tamadon, Armin Amiri, Leila Mahmoodnia   +3 more
doaj   +4 more sources

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
A Deshpande, A Liberati, A Niklasson, Abdur Rahman Khan, Abed AlLehibi, Alex J. Sutton, Aref A. Bin Abdulhak, AZ Mat Saad, BT Batuwitage, C Bavishi, C Cahir, CM Wilcox, CS Eom, CS Kwok, D Ahrens, DF Stroup, DL Bhatt, DO Lowe, F Sierra, Faisal A. Alasmari, GH Guyatt, Imad M. Tleyjeh, J Johnstone, J Leonard, J Theisen, J Thorens, J Zhang, JL Peters, JM Boyce, JS Bajaj, KH Wilson, Larry M. Baddour, LC McDonald, LK Archibald, M Charlot, M Egger, Markus M. Heimesaat, MD Howell, MD Redelings, MM Nerandzic, Mohamad Al Tannir, Muhammad Riaz, Musa A. Garbati, Mushabab AlGhamdi, Patricia J. Erwin, PK Kutty, PS Yachimski, R DerSimonian, R Scagliarini, RL Jump, S Dial, S Janarthanan, S Jayatilaka, S Linney, S Schneeweiss, SG Moreno, SG Moreno, Talal Ibrahim, WR Jarvis   +58 more
core   +14 more sources

Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study [PDF]

, 2010
A case-control study comprising 1315 Campylobacter jejuni cases, 121 Campylobacter coli cases and 3409 frequency-matched controls was conducted in The Netherlands in 2002-2003. Risk factors for both C. jejuni and C.
Brandhof, W.E., van den, Breukink, B.J., Doorduyn, Y., Duynhoven, Y.T.H.P., van, Pelt, W., van, Wagenaar, J.A.   +5 more
core   +6 more sources

Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. [PDF]

PLoS ONE, 2018
BACKGROUND:Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease.
Hee Jeong Lee, Haekyung Lee, Song Hee Oh, Joonbyung Park, Suyeon Park, Jin Seok Jeon, HyunJin Noh, Dong Cheol Han, Soon Hyo Kwon   +8 more
doaj   +1 more source

Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report

Journal of Medical Case Reports, 2021
Background Proton pump inhibitors are frequently used (and often overused) medications with adverse effects including vitamin B12 deficiency, Clostridium difficile colitis, and increased risk of chronic kidney disease.
Theodore W. Perry
doaj   +1 more source

Proton Pump Inhibitors

World Chinese Journal of Digestology, 2013
Proton pump inhibitors (PPIs), omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole bind irreversibly to the H+, K+- ATPase (the “proton pump”) inhibiting its activity and decreasing gastric acid production.
Nghia H. Pham, Brian A. Baldo
openaire   +4 more sources

Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis [PDF]

, 2005
Aim: To systematically evaluate the efficacy of H2-receptor antagonists (H2RAs) and proton pump inhibitors in healing erosive esophagitis (EE). Methods: A meta-analysis was performed.
Huang, JQ, Lam, SK, Wang, WH, Wong, BCY, Wong, WM, Xia, HHX, Zheng, GF   +6 more
core   +1 more source

Proton pump inhibitors are associated with increased risk of development of chronic kidney disease [PDF]

, 2016
Background Acute interstitial nephritis secondary to proton pump inhibitors (PPIs) frequently goes undiagnosed due to its subacute clinical presentation, which may later present as chronic kidney disease (CKD).
Arora, Pradeep, Carter, Randolph L., Golzy, Mojgan, Gupta, Anu, Jalal, Kabir, Lohr, James W., Patel, Nilang   +6 more
core   +2 more sources

Risk of Bacterial Infection from Proton Pump Inhibitor Use

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Currently, proton pump inhibitors are used in a wide range of patients with gastroesophageal reflux disease, peptic ulcer, and upper gastrointestinal symptoms such as dyspepsia.
Sung Soo Kim, Yunju Jo, Seun Ja Park, Jeong Seop Moon, Dong Ho Lee, Jae Jun Kim, Yong Chan Lee, Ethics and Education Committee of Korean College of Helicobacter and Upper Gastrointestinal Research   +7 more
doaj   +1 more source

Esophageal sphincter device for gastroesophageal reflux disease [PDF]

, 2013
BACKGROUND Patients with gastroesophageal reflux disease who have a partial response to proton-pump inhibitors often seek alternative therapy. We evaluated the safety and effectiveness of a new magnetic device to augment the lower esophageal sphincter ...
Bemelman, Willem A, Dunn, Dan, Dunst, Christy M, Edmundowicz, Steven A, Ganz, Robert A, Horgan, Santiago, Lipham, John C, Luketich, James D, Melvin, W. Scott, Oelschlager, Brant K, Peters, Jeffrey H, Schlack-Haerer, Steven C, Smith, C. Daniel, Smith, Christopher C, Taiganides, Paul A   +14 more
core   +2 more sources